CLC

Summary

CLC (Charcot-Leyden crystal galectin, HGNC:2014) is a protein-coding gene on chromosome 19q13.2, encoding Galectin-10 (Q05315). Regulates immune responses through the recognition of cell-surface glycans.

Lysophospholipases are enzymes that act on biological membranes to regulate the multifunctional lysophospholipids. The protein encoded by this gene is a lysophospholipase expressed in eosinophils and basophils. It hydrolyzes lysophosphatidylcholine to glycerophosphocholine and a free fatty acid. This protein may possess carbohydrate or IgE-binding activities. It is both structurally and functionally related to the galectin family of beta-galactoside binding proteins. It may be associated with inflammation and some myeloid leukemias.

Source: NCBI Gene 1178 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 16 total
• MANE Select transcript: NM_001828

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2014
Approved symbol	CLC
Name	Charcot-Leyden crystal galectin
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	LGALS10, MGC149659, Gal-10
Ensembl gene	ENSG00000105205
Ensembl biotype	protein_coding
OMIM	153310
Entrez	1178

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000221804

RefSeq mRNA: 1 — MANE Select: NM_001828 NM_001828

CCDS: CCDS33025

Canonical transcript exons

ENST00000221804 — 4 exons

Exon	Start	End
ENSE00000706193	39734283	39734493
ENSE00000877644	39734997	39735073
ENSE00000877645	39731255	39731505
ENSE00001477760	39737938	39738029

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 99.74.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 6.1167 / max 2053.0092, expressed in 106 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180898	3.3783	72
180899	2.7384	79

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trabecular bone tissue	UBERON:0002483	99.74	gold quality
bone marrow	UBERON:0002371	98.48	gold quality
bone marrow cell	CL:0002092	96.47	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	96.08	gold quality
monocyte	CL:0000576	95.79	gold quality
mononuclear cell	CL:0000842	95.52	gold quality
bone element	UBERON:0001474	95.45	gold quality
blood	UBERON:0000178	94.75	gold quality
leukocyte	CL:0000738	94.56	gold quality
gall bladder	UBERON:0002110	85.51	gold quality
vermiform appendix	UBERON:0001154	81.98	gold quality
caecum	UBERON:0001153	78.06	gold quality
granulocyte	CL:0000094	75.63	gold quality
mucosa of transverse colon	UBERON:0004991	74.50	gold quality
spleen	UBERON:0002106	74.14	gold quality
ileal mucosa	UBERON:0000331	73.52	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.73	gold quality
rectum	UBERON:0001052	70.27	gold quality
smooth muscle tissue	UBERON:0001135	70.21	gold quality
Brodmann (1909) area 10	UBERON:0013541	67.32	gold quality
jejunal mucosa	UBERON:0000399	66.59	gold quality
amniotic fluid	UBERON:0000173	62.28	gold quality
duodenum	UBERON:0002114	62.11	gold quality
germinal epithelium of ovary	UBERON:0001304	61.17	silver quality
right lung	UBERON:0002167	60.06	gold quality
parietal pleura	UBERON:0002400	59.73	gold quality
frontal pole	UBERON:0002795	59.60	gold quality
paraflocculus	UBERON:0005351	59.59	gold quality
middle frontal gyrus	UBERON:0002702	59.48	gold quality
thymus	UBERON:0002370	59.27	silver quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	57049.25
E-MTAB-10432	yes	39737.35
E-MTAB-9801	yes	32965.83
E-MTAB-9067	yes	14722.05
E-MTAB-6505	yes	13673.34
E-CURD-6	yes	3354.27
E-CURD-55	yes	3009.74
E-CURD-77	yes	539.50
E-MTAB-8207	yes	300.07
E-MTAB-7249	yes	11.12
E-HCAD-10	yes	7.93
E-ANND-3	yes	3.49
E-MTAB-6678	no	3.51

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1H2, PAX1, POLR2B, PRDM16, RUNX2, SMARCA1, STAT1, TBP, YY1

miRNA regulators (miRDB)

9 targeting CLC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3616-5P	99.55	67.02	989
HSA-MIR-573	99.55	67.44	955
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-4722-5P	98.46	66.34	1611
HSA-MIR-541-5P	98.24	67.77	1181
HSA-MIR-4433A-3P	97.75	62.82	1435
HSA-MIR-212-5P	96.83	67.43	950

Literature-anchored findings (GeneRIF, showing 23)

• downregulated significantly in acute myeloid leukemia patients whose white blood cell count was higher than 100 x 10(9)/L cells (PMID:12031912)
• Changes in the expressions of galectin-10 are potentially important for myeloid cell differentiation into specific lineages. (PMID:12714580)
• The five genes, and three of the encoded proteins, were shown differentially expressed between a group of keratoconus patients and a reference group using different techniques (PMID:16015083)
• Downregulated in whole blood of infants hospitalised with respiratory syncytial virus (RSV), subtype B, bronchiolitis. (PMID:17166282)
• expressed in human T lymphocytes, galectin-10 is essential for the functional properties of CD25(+) Treg cells. (PMID:17502455)
• Genetic variation in Charcot-Leyden crystal protein was found to be associated with allergic rhinitis (PMID:19650845)
• Data show that galectin-10 expression was related to the histological grade and with the number of eosinophils in the lesion. (PMID:19758173)
• DK-PGD-induced CLC/Gal-10 mRNA level can serve as a potential marker for monitoring pharmacodynamic effects of blood exposure to CRTH2 modulating agents (PMID:20858065)
• CLC and IFNAR1 were identified to be overall differentially expressed between early- and late-onset CRC, and are important in the development of early-onset CRC. (PMID:21716316)
• The results support the potential for galectin-10 to be used as a surrogate biomarker of eosinophilic airway inflammation. (PMID:22880030)
• findings show that galectin-10 functions as a T cell-suppressive molecule in eosinophils (PMID:28515279)
• Because Trp72 is the highly conserved in the ligand binding sites of galectins, we used EGFP-tagged W72A to show that Gal-10 could not be transported into the nucleus, indicating that Trp72 is crucial for Gal-10 transport into that organelle. (PMID:30239701)
• Increased CLC/Gal-10 and MBP-1 levels in the sputum were strongly correlated with sputum eosinophils in patients with asthma. CLC/Gal-10 and MBP-1 may be useful biomarkers for differentiation of eosinophilic airway inflammation in asthma. (PMID:31157540)
• CLC mRNA levels based on the qRT-PCR may serve as a reliable and alternative method for the identification of eosinophilic chronic rhinosinusitis with nasal polyps (PMID:31269798)
• Galectin-10, the protein that forms Charcot-Leyden crystals, is not stored in granules but resides in the peripheral cytoplasm of human eosinophils. (PMID:32108369)
• [Expression and pathological role of galectin-10 in different types of nasal polyps]. (PMID:32911886)
• Identification of galectin10 as a biomarker for periodontitis based on proteomic analysis of gingival crevicular fluid. (PMID:33300083)
• Chronic rhinosinusitis with nasal polyposis (CRSwNP): the correlation between expression of Galectin-10 and Clinical-Cytological Grading (CCG). (PMID:34647485)
• Crystalline State Determines the Potency of Galectin-10 Protein Assembly to Induce Inflammation. (PMID:35274950)
• Galectin-10 as a Potential Biomarker for Eosinophilic Diseases. (PMID:36291593)
• Glutathione disrupts galectin-10 Charcot-Leyden crystal formation to possibly ameliorate eosinophil-based diseases such as asthma. (PMID:36988350)
• Behcet syndrome: The disturbed balance between anti- (CLEC12A, CLC) and proinflammatory (IFI27) gene expressions. (PMID:37102643)
• Eosinophil-derived galectin-10 upregulates matrix metalloproteinase expression in bullous pemphigoid blisters. (PMID:37640566)

Cross-species orthologs

23 orthologs

Organism	Symbol	Gene ID
danio_rerio	lgals3b	ENSDARG00000044001
danio_rerio	si:ch211-10a23.2	ENSDARG00000060656
danio_rerio	si:dkey-95h12.2	ENSDARG00000092923
drosophila_melanogaster	galectin	FBGN0031213
drosophila_melanogaster	CG11374	FBGN0031214
drosophila_melanogaster	CG13950	FBGN0031289
caenorhabditis_elegans		WBGENE00002264
caenorhabditis_elegans		WBGENE00002266
caenorhabditis_elegans		WBGENE00002269
caenorhabditis_elegans		WBGENE00002270
caenorhabditis_elegans		WBGENE00002271
caenorhabditis_elegans		WBGENE00004165
caenorhabditis_elegans	C27C7.5	WBGENE00007768
caenorhabditis_elegans	F46A8.3	WBGENE00009746
caenorhabditis_elegans	F46A8.4	WBGENE00009747
caenorhabditis_elegans	F46A8.5	WBGENE00009748
caenorhabditis_elegans	F46A8.8	WBGENE00009751
caenorhabditis_elegans		WBGENE00017080
caenorhabditis_elegans		WBGENE00018255
caenorhabditis_elegans		WBGENE00018649
caenorhabditis_elegans		WBGENE00018650
caenorhabditis_elegans		WBGENE00018651
caenorhabditis_elegans		WBGENE00235368

Paralogs (16): LGALS14 (ENSG00000006659), LGALS2 (ENSG00000100079), LGALS1 (ENSG00000100097), LGALS13 (ENSG00000105198), LGALS8 (ENSG00000116977), LGALSL (ENSG00000119862), LGALS3 (ENSG00000131981), LGALS12 (ENSG00000133317), LGALS9 (ENSG00000168961), LGALS9B (ENSG00000170298), LGALS4 (ENSG00000171747), LGALS9C (ENSG00000171916), LGALS7B (ENSG00000178934), LGALS7 (ENSG00000205076), LGALS16 (ENSG00000249861), GRIFIN (ENSG00000275572)

Protein

Protein identifiers

Galectin-10 — Q05315 (reviewed: Q05315)

Alternative names: Charcot-Leyden crystal protein, Eosinophil lysophospholipase, Lysolecithin acylhydrolase

All UniProt accessions (1): Q05315

UniProt curated annotations — full annotation on UniProt →

Function. Regulates immune responses through the recognition of cell-surface glycans. Essential for the anergy and suppressive function of CD25-positive regulatory T-cells (Treg).

Subunit / interactions. Interacts with CEL.

Subcellular location. Cytoplasm. Cytosol. Cytoplasmic granule.

Tissue specificity. Expressed abundantly in the bone marrow. Expressed exclusively by eosinophils and basophils. Not detected in monocytes and neutrophils. Expressed in CD25-positive regulatory T-cells (Treg) (at protein level). Found in intestinal tissue from patients with Celiac disease, expression is directly related to the histological grade of mucosal damage and to the number of eosinophils found in the duodenal lesion (at protein level). Found in sputum of patients with eosinophilic inflammatory diseases such as asthma (at protein level).

Miscellaneous. Forms hexagonal bipyramidal crystals, known as Charcot-Leyden crystals, in tissues and secretions from sites of eosinophil-associated inflammation and some myeloid leukemias.

RefSeq proteins (1): NP_001819* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001079	Galectin_CRD	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR044156	Galectin-like	Family

Pfam: PF00337

Enzyme classification (BRENDA):

• EC 3.1.1.5 — lysophospholipase (BRENDA: 46 organisms, 226 substrates, 153 inhibitors, 43 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

35 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
LYSOPHOSPHATIDYLCHOLINE	0.022–0.26	5
1-OLEOYL-2-LYSOPHOSPHATIDYLCHOLINE	0.306–0.75	2
1-PALMITOYL LYSOPHOSPHATIDYLCHOLINE	0.0273–0.19	2
1-PALMITOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	0.0606–0.17	2
PHOSPHATIDYLCHOLINE	0.18–0.63	2
1,2-DIDECANOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	1	1
1,2-DIDECANOYLPHOSPHATIDYLCHOLINE	1.1	1
1,2-DIOCTANOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	2.9	1
1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	0.82	1
1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE	0.19	1
1-(4Z,7Z,10Z,13Z,16Z,19Z)-DOCOSAHEXAENOYL-2-LYSO	0.045	1
1-ACYL-2-OLEOYL-PHOSPHATIDYLCHOLINE	1.6	1
1-ARACHIDONOYL-2-LYSOPHOSPHATIDYLCHOLINE	0.0676	1
1-DOCOSAHEXAENOYL LYSOPHOSPHATIDYLCHOLINE	0.045	1
1-HEXANOYL LYSOPHOSPHATIDYLCHOLINE	0.0992	1

UniProt features (19 total): strand 10, helix 2, initiator methionine 1, chain 1, turn 1, domain 1, site 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

47 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
6GKS	X-RAY DIFFRACTION	1.38
6QRN	X-RAY DIFFRACTION	1.4
5XRG	X-RAY DIFFRACTION	1.55
5XRH	X-RAY DIFFRACTION	1.55
9UWN	X-RAY DIFFRACTION	1.57
9UWP	X-RAY DIFFRACTION	1.57
5XRN	X-RAY DIFFRACTION	1.6
5XRO	X-RAY DIFFRACTION	1.6
9UWK	X-RAY DIFFRACTION	1.6
6A1U	X-RAY DIFFRACTION	1.62
8JAE	X-RAY DIFFRACTION	1.62
6A1S	X-RAY DIFFRACTION	1.63
6A1Y	X-RAY DIFFRACTION	1.63
9UWO	X-RAY DIFFRACTION	1.64
5XRI	X-RAY DIFFRACTION	1.68
5XRK	X-RAY DIFFRACTION	1.7
6L6C	X-RAY DIFFRACTION	1.77
9UWS	X-RAY DIFFRACTION	1.78
1G86	X-RAY DIFFRACTION	1.8
1HDK	X-RAY DIFFRACTION	1.8
1LCL	X-RAY DIFFRACTION	1.8
1QKQ	X-RAY DIFFRACTION	1.8
6L6B	X-RAY DIFFRACTION	1.8
6L6A	X-RAY DIFFRACTION	1.81
5XRJ	X-RAY DIFFRACTION	1.9
6GLW	X-RAY DIFFRACTION	1.9
6GKU	X-RAY DIFFRACTION	1.91
6L68	X-RAY DIFFRACTION	1.92
8YQC	X-RAY DIFFRACTION	1.92
6L6D	X-RAY DIFFRACTION	1.93

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q05315-F1	96.95	0.96

Antibody-complex structures (SAbDab): 3 — 6GKU, 6GLW, 6GLX

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 136 (not glycosylated)

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 163 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, FXR_IR1_Q6, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, MYOGENIN_Q6, GOBP_TOLERANCE_INDUCTION, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GCANCTGNY_MYOD_Q6, TGACCTY_ERR1_Q2, HNF1_Q6, GOBP_REGULATION_OF_TOLERANCE_INDUCTION, GGGTGGRR_PAX4_03, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, AACWWCAANK_UNKNOWN, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_DN, GOBP_REGULATION_OF_IMMUNE_RESPONSE

GO Biological Process (4): regulation of T cell anergy (GO:0002667), regulation of T cell cytokine production (GO:0002724), regulation of activated T cell proliferation (GO:0046006), T cell apoptotic process (GO:0070231)

GO Molecular Function (3): carbohydrate binding (GO:0030246), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), extracellular matrix (GO:0031012), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular anatomical structure	2
regulation of T cell tolerance induction	1
T cell anergy	1
regulation of lymphocyte anergy	1
T cell cytokine production	1
regulation of T cell mediated immunity	1
regulation of cytokine production involved in immune response	1
regulation of T cell proliferation	1
activated T cell proliferation	1
lymphocyte apoptotic process	1
protein binding	1
cytoplasm	1
external encapsulating structure	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

650 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLC	GALE	Q14376	932
CLC	LGALS2	P05162	699
CLC	LGALS12	Q96DT0	608
CLC	CHD7	Q9P2D1	601
CLC	RNASE2	P10153	581
CLC	LGALS3	P17931	576
CLC	EPX	P11678	571
CLC	GALK1	P51570	571
CLC	RNASE3	P12724	570
CLC	ISYNA1	Q9NPH2	540
CLC	ADH1A	P07327	517
CLC	HDAC3	O15379	510
CLC	PAICS	P22234	507
CLC	HDAC8	Q9BY41	492
CLC	PRG2	P13727	480

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CLC	CLC	psi-mi:“MI:0915”(physical association)	0.670
CLC	CLC	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (2): CLC (Two-hybrid), CLC (Two-hybrid)

ESM2 similar proteins: A0A3Q1N1R0, A4D1Z8, A8MUM7, D3ZGS3, O00214, O08573, O14727, O23547, O44126, O54891, O88644, O88879, P07583, P08520, P11762, P23668, P26788, P36573, P38552, P47967, P56180, P56217, P56470, P79238, P97400, P97840, Q01968, Q05315, Q09581, Q09605, Q29058, Q3MHZ8, Q62665, Q6DGJ1, Q6NVF0, Q801X7, Q8C726, Q8K419, Q8LEV3, Q8TCE9

Diamond homologs: A8MUM7, O00182, O08573, O54891, P38486, P38552, P47929, P79238, P97400, P97840, Q05315, Q29058, Q3B8N2, Q3MHZ8, Q3T0D6, Q6DKI2, Q8K419, Q8TCE9, Q9UHV8, A8N3G7, C0HJQ1, C0HJR3, O44126, O54974, P08520, P08699, P09382, P11116, P16110, P17931, P36573, P47845, P47953, P47967, P56470, P81184, P97590, Q09581, Q1ECW6, Q206Z5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

16 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	11
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:39734319:A:C	F89L	0.951
19:39734319:A:T	F89L	0.951
19:39734321:A:G	F89L	0.951
19:39731473:A:C	F112L	0.939
19:39731473:A:T	F112L	0.939
19:39731475:A:G	F112L	0.939
19:39734412:A:C	F58L	0.913
19:39734412:A:T	F58L	0.913
19:39734414:A:G	F58L	0.913
19:39734337:A:C	F83L	0.911
19:39734337:A:T	F83L	0.911
19:39734339:A:G	F83L	0.911
19:39734430:G:C	F52L	0.895
19:39734430:G:T	F52L	0.895
19:39734432:A:G	F52L	0.895
19:39734466:G:C	F40L	0.892
19:39734466:G:T	F40L	0.892
19:39734468:A:G	F40L	0.892
19:39734287:T:G	Y100S	0.878
19:39734999:G:C	F30L	0.866
19:39734999:G:T	F30L	0.866
19:39735001:A:G	F30L	0.866
19:39734370:C:A	W72C	0.860
19:39734370:C:G	W72C	0.860
19:39734386:C:G	R67P	0.858
19:39734467:A:G	F40S	0.849
19:39734372:A:G	W72R	0.848
19:39734372:A:T	W72R	0.848
19:39734308:A:G	I93T	0.847
19:39734288:A:G	Y100H	0.838

dbSNP variants (sampled 300 via entrez): RS1000900444 (19:39736792 A>T), RS1001076151 (19:39737083 C>G,T), RS1001641615 (19:39737890 T>C,G), RS1001874840 (19:39734039 A>G), RS1002019444 (19:39731969 G>A,C), RS1002910765 (19:39739148 T>C), RS1002956488 (19:39738092 TCA>T), RS1003020204 (19:39733850 T>A,C), RS1003370739 (19:39735080 G>A,C), RS1003549246 (19:39735356 T>C), RS1003886458 (19:39733557 A>C,G), RS1003938946 (19:39733760 T>A), RS1004446928 (19:39738408 C>T), RS1004584434 (19:39732235 C>T), RS1005068796 (19:39738946 A>C)

Disease associations

OMIM: gene MIM:153310 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001851_5	Schizophrenia	2.000000e-06
GCST004600_109	Eosinophil percentage of white cells	4.000000e-53
GCST004606_38	Eosinophil count	6.000000e-58
GCST004617_36	Eosinophil percentage of granulocytes	2.000000e-47
GCST004623_96	Neutrophil percentage of granulocytes	2.000000e-33
GCST005975_3	Eosinophil count	1.000000e-12
GCST90002379_153	Basophil count	4.000000e-13
GCST90002380_18	Basophil percentage of white cells	4.000000e-18
GCST90002380_19	Basophil percentage of white cells	3.000000e-11
GCST90002381_343	Eosinophil count	9.000000e-134
GCST90002382_465	Eosinophil percentage of white cells	3.000000e-129

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0007991	eosinophil percentage of leukocytes
EFO:0004842	eosinophil count
EFO:0007996	eosinophil percentage of granulocytes
EFO:0007994	neutrophil percentage of granulocytes
EFO:0005090	basophil count
EFO:0007992	basophil percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic Trioxide	increases expression	2
bisphenol F	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
coumarin	affects phosphorylation	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Aspirin	affects response to substance	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression	1
Iron	decreases expression	1
Ozone	affects expression, increases abundance	1
Tretinoin	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.